Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?

Cole Maguire; Teresa Frohman; Scott S. Zamvil; Elliot Frohman; Esther Melamed

doi:10.1212/NXI.0000000000000811

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?

Cole Maguire, Teresa Frohman, Scott S. Zamvil, Elliot Frohman, Esther Melamed

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	Neurology(R) neuroimmunology & neuroinflammation
Volume	7
Issue number	5
DOIs	https://doi.org/10.1212/NXI.0000000000000811
State	Published - Sep 1 2020
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1212/NXI.0000000000000811

Cite this

@article{8c9e5138b6a84c58ac0c7031c30720f4,

title = "Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?",

author = "Cole Maguire and Teresa Frohman and Zamvil, {Scott S.} and Elliot Frohman and Esther Melamed",

year = "2020",

month = sep,

day = "1",

doi = "10.1212/NXI.0000000000000811",

language = "English (US)",

volume = "7",

journal = "Neurology(R) neuroimmunology & neuroinflammation",

issn = "2332-7812",